Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 451–460 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 451

    Medicine slug
    dipyridamole
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 1-2.5 L/kg

      Numeric value
      1
      Unit
      L/kg
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9bd34108-9d98-c4ca-e053-2995a90a2bc8 (opens source in a new tab)

        Dipyridamole label

        Version not recorded · Effective date not recorded

        The average total body clearance is 2.3-3.5 mL/min/kg, with an apparent volume of distribution at steady state of 1-2.5 L/kg and a central apparent volume of 3-5 liters.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20 (opens source in a new tab)

        Dipyridamole label

        Version not recorded · Effective date not recorded

        The average total body clearance is 2.3-3.5 mL/min/kg, with an apparent volume of distribution at steady state of 1-2.5 L/kg and a central apparent volume of 3-5 liters.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6093dcd9-82d2-414f-8507-eda22c14f626 (opens source in a new tab)

        Dipyridamole label

        Version not recorded · Effective date not recorded

        The average total body clearance is 2.3-3.5 mL/min/kg, with an apparent volume of distribution at steady state of 1-2.5 L/kg and a central apparent volume of 3-5 liters.

  2. Projected row 452

    Medicine slug
    disopyramide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 6.7 hours

      Numeric value
      6.7
      Unit
      hours
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31e79459-107f-4d69-a163-90014f1c4772 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11a68e26-d2e4-48f6-ba0f-9bdd5778f25a (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3acbcef2-04ec-1ab1-b855-d1244b0e8006 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2aa1642-d262-4520-bc6a-9fd3ad795677 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours).

  3. Projected row 453

    Medicine slug
    disopyramide
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    4
    Source count
    4
    Agreement rate
    1
    Recorded readings

    1. 50%

      Numeric value
      50
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:31e79459-107f-4d69-a163-90014f1c4772 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/ml, and at these concentrations protein binding varies from 50% to 65%.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11a68e26-d2e4-48f6-ba0f-9bdd5778f25a (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/mL, and at these concentrations protein binding varies from 50% to 65%.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3acbcef2-04ec-1ab1-b855-d1244b0e8006 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/mL, and at these concentrations protein binding varies from 50% to 65%.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2aa1642-d262-4520-bc6a-9fd3ad795677 (opens source in a new tab)

        Disopyramide label

        Version not recorded · Effective date not recorded

        The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/ml, and at these concentrations protein binding varies from 50% to 65%.

  4. Projected row 454

    Medicine slug
    divalproex
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    128
    Source count
    51
    Agreement rate
    1
    Recorded readings

    1. 89%

      Numeric value
      89
      Unit
      %
      Source records
      51

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 51 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a9f5f24-e421-406f-ac91-d1f964245f54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b12c694-e120-45f6-ad28-36373e2c5378 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83a77f60-ed58-4fa0-a584-e6a0c767d19d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f081c74-9f73-4ed9-9157-8d73d586a409 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d4129ae-0ce8-4a04-9f9d-c770508de8ed (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46b2e8a9-5d50-d0b2-e063-6294a90a1b47 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:177e34e9-f74d-42aa-8e3c-5fb4f41c2322 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b3cb30a-8d81-4aa9-bdb4-19413ae5fedf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef472176-7f98-4f88-be5e-a101fecb46fd (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID or QID.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6af40b06-0a92-454c-9277-80e89de27231 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8e954d4-54e3-491c-867c-b3b656b70f23 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41e32cd5-1393-4ef1-81cb-8e3795e30682 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e96b724-5f5f-43cb-8d8b-adff3e1fc779 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352b4c3c-e419-4827-9e00-febb0164e0f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3df910c5-b6f0-4a65-9640-b702ecea49f9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4a815eb-ea20-482a-bb67-06ab34264515 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eee54a6-5b4c-330d-e063-6394a90a9f18 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:533245ba-7088-c929-e063-6294a90abe1d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbe7d9b9-70e4-4531-a24f-5918966d94f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ef6c5fd-42b2-4419-9b5a-e6d63571e3a0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:283af6d2-8ea2-4225-b2e7-a2057dbdb793 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID or QID.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aab6b411-11e9-4a16-afb6-d471ba4756e9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa386ae3-ceac-4e3b-8fb1-ced3107a4c54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0669ac77-10df-48af-bc42-55e768b69e4f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b12b76a0-4b6e-4cd4-9508-10a2c84d8beb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:392df14f-4d65-4be9-973b-1f0ce1013d8f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa823ee0-0c69-6b85-da1e-9bb2e2150ea5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d524db34-99c4-4837-a532-a619f82c21ba (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b41cd15-9981-4d44-9c4b-e84168d86453 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID or QID.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e5fcf5b1-263e-43e0-9424-e613d5cca3fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d48af379-bd5d-48e1-ad2d-86c493d9cbea (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6240cee7-6aa8-425c-ba46-f889a640f0fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad5e8bd8-c923-40f0-a106-55620c4247d7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a8ba3986-1ded-44a8-8d10-d0f252a07794 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dc024ce-efc8-4690-7cb5-639c728fccac (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, Depakote ER given once daily produced an average bioavailability of 89% relative to an equal total daily dose of Depakote given BID, TID, or QID.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00332c65-edad-a153-9c78-628931daa732 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3352ee-a240-43ff-a243-29ad2bc989c7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID or QID.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e35f833-1cf7-12eb-9567-7a191e32e138 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:66b0a3e0-70df-469e-845f-17769482304b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d6ddb5-7143-4917-baf7-31cbf8a90e8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf34dd25-abe3-4587-b481-df052f085429 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8cc336b-5191-7f8b-e053-2a95a90a6acb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:319bbead-bec8-4bb7-9ecb-b2e161c44b8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94eac383-a89f-4128-b81c-076640b8edcf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f5bb45e-836b-48ce-9764-2d50edcb202c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0822300b-68c0-4e70-b1ba-8eb42cf373f7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b367d81d-4eca-4e28-b490-34be4c003561 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aec1944-86a1-490c-a734-d9dd3b52c9d6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a9f020-f7a1-44e2-a452-f0e37bd3e077 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33f07aac-4dc5-4f97-976a-a84f93497bc6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        In five multiple-dose studies in healthy subjects (N = 82) and in subjects with epilepsy (N = 86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID or QID.

  5. Projected row 455

    Medicine slug
    divalproex
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    128
    Source count
    128
    Agreement rate
    1
    Recorded readings

    1. 9 to 16 hours

      Numeric value
      9
      Unit
      hours
      Source records
      128

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 128 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec1a441-218a-4c80-a0cb-69bcc327f472 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34c4504-5409-406e-995b-138e5f700242 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a9f5f24-e421-406f-ac91-d1f964245f54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b12c694-e120-45f6-ad28-36373e2c5378 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:699a9722-27bd-4e90-819b-d4ecb99466c8 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbaff0ae-431e-4e83-81c2-41eb4b18ee87 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83a77f60-ed58-4fa0-a584-e6a0c767d19d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f081c74-9f73-4ed9-9157-8d73d586a409 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33798a7c-c5a9-49a5-be5d-1312910ef468 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6316061c-9758-4f38-9cb2-7ca833dd20bf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:773a289b-65ed-4045-80c5-f00e28c1c079 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d4129ae-0ce8-4a04-9f9d-c770508de8ed (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb94bbb1-07c1-49be-8c2c-f5635c65366d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64797788-fdcb-4d12-a1a4-743ad71bd17b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46b2e8a9-5d50-d0b2-e063-6294a90a1b47 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:177e34e9-f74d-42aa-8e3c-5fb4f41c2322 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8d9cd69-ceca-3057-9d1c-12c44b19f767 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b3cb30a-8d81-4aa9-bdb4-19413ae5fedf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df8f3825-a037-4343-859d-e59bca5f1e43 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79e6dc26-a38b-4642-a216-1fa1213b919a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71296464-0c09-4ff2-beb3-377af77dc4cf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef472176-7f98-4f88-be5e-a101fecb46fd (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbd47222-14f1-4588-a009-9b81b55ca60d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6af40b06-0a92-454c-9277-80e89de27231 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8e954d4-54e3-491c-867c-b3b656b70f23 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5926c3ff-c995-4789-941c-d38aa7db94dc (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41e32cd5-1393-4ef1-81cb-8e3795e30682 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19064624-81d1-4ce3-bfe4-955bad6af6a2 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:589ae3a6-8b2e-d931-d36b-1937287ab5c0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9cfdcb58-d6d7-43bb-b6e1-17172b143296 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15f8a5be-e269-2e07-60d9-1dd7bf5f5281 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb39a94e-93e6-4afe-a300-f80e8f1e0fa6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304a23-4a5f-47bc-9687-4044b43f7a20 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab8616a5-ea72-4df7-b095-54ea19ef6fba (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b95494e2-ee7a-7415-e053-2995a90ae852 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e96b724-5f5f-43cb-8d8b-adff3e1fc779 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352b4c3c-e419-4827-9e00-febb0164e0f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3df910c5-b6f0-4a65-9640-b702ecea49f9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4a815eb-ea20-482a-bb67-06ab34264515 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:388fd4bc-f12f-4e55-a1e7-72aa585519fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63d61062-2700-47f4-8ab4-3bd641b81fe1 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8f72850-92d5-4f64-b9f1-657f72bfa15a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fb57229-08ef-44d6-b40a-92b2f96ff795 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca6bbec6-5631-4436-957e-fb8707e1683d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15ffe3d8-d483-4c45-adc4-1cc8a5b68d19 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd6fe37a-d26d-4ae8-a894-b44878e6bf8e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d67af03a-5261-4358-8787-2e729267ff7e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eee54a6-5b4c-330d-e063-6394a90a9f18 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f936b9d0-a58f-4fa5-8db9-752dabb837a6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1107f190-bef1-41cb-9393-8479b0a56040 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbd1d178-77a3-46ff-985d-307dffaed1ad (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed710c62-8ba6-4f19-b240-3ee73cd03d67 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:533245ba-7088-c929-e063-6294a90abe1d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f911748c-fb3a-fe1a-ab2a-4b40455e05ef (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35a91dd3-19d0-09cb-e063-6394a90af01b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35a95333-9fc1-7a9f-e063-6294a90a9f30 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbe7d9b9-70e4-4531-a24f-5918966d94f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ef6c5fd-42b2-4419-9b5a-e6d63571e3a0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:283af6d2-8ea2-4225-b2e7-a2057dbdb793 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed24bb3a-bba1-4b27-8733-96619793fc15 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce12c7b1-caa9-4224-bb5f-3e20e0281d66 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bef10ed-e4b5-95ae-e063-6294a90a86eb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64b509bc-f398-48ad-bdcb-9904e61d9225 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79132bea-04d8-4dd9-bd31-07f0ba805c21 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fea19b14-d8ed-4954-bc54-b9240f78b3c3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ead614c-a68d-4a2f-94d0-e6404a8f8760 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aab6b411-11e9-4a16-afb6-d471ba4756e9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55f1614b-aadc-34ca-e063-6394a90ae2a7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa386ae3-ceac-4e3b-8fb1-ced3107a4c54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a76f9909-28c9-4eb7-8ffd-ff6222fea079 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abac11e6-7ce1-491c-9ac3-61f3df54c4a4 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38f4f2fd-400b-ccc4-e063-6294a90a5f41 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0669ac77-10df-48af-bc42-55e768b69e4f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b12b76a0-4b6e-4cd4-9508-10a2c84d8beb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4619aff4-0f80-444f-858d-42e4137aa809 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf15569c-5010-4e9b-aef0-7df4de5ed04e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e86a610-45ef-4be7-a3ab-f656f5b32706 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a67855ff-a879-43f0-bca3-94c304348bf5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90225548-85a8-4ea7-95d3-e8231c36fe5a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:392df14f-4d65-4be9-973b-1f0ce1013d8f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa823ee0-0c69-6b85-da1e-9bb2e2150ea5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d524db34-99c4-4837-a532-a619f82c21ba (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b41cd15-9981-4d44-9c4b-e84168d86453 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea5c5e3c-c23f-4ec0-b1ab-6b317f3d2f91 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e5fcf5b1-263e-43e0-9424-e613d5cca3fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d48af379-bd5d-48e1-ad2d-86c493d9cbea (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6240cee7-6aa8-425c-ba46-f889a640f0fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ecfe765-d743-4308-9cd9-4a7b1a229ea9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3af30e3-27ff-4285-8e4a-81856f266b32 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad5e8bd8-c923-40f0-a106-55620c4247d7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48a6e47a-3697-492d-9086-56e4ca0151e5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e4778d8-8798-4da1-bb33-1aa1414b5809 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57b71a0b-c2bf-4326-9c26-0f2fe56bf5bc (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a8ba3986-1ded-44a8-8d10-d0f252a07794 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4834732f-6044-946c-e063-6394a90a5da3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08a65cf4-7749-4ceb-6895-8f4805e2b01f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dc024ce-efc8-4690-7cb5-639c728fccac (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00332c65-edad-a153-9c78-628931daa732 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3352ee-a240-43ff-a243-29ad2bc989c7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:547d8305-bfc5-f4da-e063-6294a90a6106 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e35f833-1cf7-12eb-9567-7a191e32e138 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:66b0a3e0-70df-469e-845f-17769482304b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a999f402-be1d-4153-b743-cfdb95ed1562 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab6fa448-7485-6644-e053-2a95a90aa181 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d6ddb5-7143-4917-baf7-31cbf8a90e8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf34dd25-abe3-4587-b481-df052f085429 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74adc5e-e92d-46a7-afdc-a6464a440bde (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8cc336b-5191-7f8b-e053-2a95a90a6acb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1d4d790-73d5-4a3b-a786-99f2c9812546 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:319bbead-bec8-4bb7-9ecb-b2e161c44b8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0816a066-9ee3-4c23-944d-3539fc2c12bf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e59609f-d79d-414b-a6fc-7efb1ba5b200 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94eac383-a89f-4128-b81c-076640b8edcf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c971b50d-0f78-422f-abee-1c5b4e1d20e7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg as valproic acid.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f5bb45e-836b-48ce-9764-2d50edcb202c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0822300b-68c0-4e70-b1ba-8eb42cf373f7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47412563-ec3e-44fd-9f3f-c00b9b09033a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b367d81d-4eca-4e28-b490-34be4c003561 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8f84c2e-5621-4435-8023-b4e090f7af02 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aec1944-86a1-490c-a734-d9dd3b52c9d6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2388bfd-7455-48ae-b396-463df0c278f0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:beba3da1-e80d-45b4-9bd6-3ed85c9482f3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a0fa934-ec8c-460e-86eb-11281728fe85 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a9f020-f7a1-44e2-a452-f0e37bd3e077 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4fc50afb-67f3-4bf3-9ec3-cc12734f47fd (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33f07aac-4dc5-4f97-976a-a84f93497bc6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 mg to 1,000 mg.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0339e27d-3dbf-4c37-a14e-f53557c08e19 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Mean terminal half-life for valproate monotherapy ranged from 9 to 16 hours following oral dosing regimens of 250 to 1,000 mg.

  6. Projected row 456

    Medicine slug
    divalproex
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    128
    Source count
    128
    Agreement rate
    1
    Recorded readings

    1. 0.56 L

      Numeric value
      0.56
      Unit
      L
      Source records
      128

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 128 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec1a441-218a-4c80-a0cb-69bcc327f472 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f34c4504-5409-406e-995b-138e5f700242 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73m 2 and 11 L/1.73m 2 , respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a9f5f24-e421-406f-ac91-d1f964245f54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b12c694-e120-45f6-ad28-36373e2c5378 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:699a9722-27bd-4e90-819b-d4ecb99466c8 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbaff0ae-431e-4e83-81c2-41eb4b18ee87 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83a77f60-ed58-4fa0-a584-e6a0c767d19d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f081c74-9f73-4ed9-9157-8d73d586a409 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33798a7c-c5a9-49a5-be5d-1312910ef468 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6316061c-9758-4f38-9cb2-7ca833dd20bf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:773a289b-65ed-4045-80c5-f00e28c1c079 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d4129ae-0ce8-4a04-9f9d-c770508de8ed (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb94bbb1-07c1-49be-8c2c-f5635c65366d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64797788-fdcb-4d12-a1a4-743ad71bd17b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:46b2e8a9-5d50-d0b2-e063-6294a90a1b47 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:177e34e9-f74d-42aa-8e3c-5fb4f41c2322 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8d9cd69-ceca-3057-9d1c-12c44b19f767 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b3cb30a-8d81-4aa9-bdb4-19413ae5fedf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df8f3825-a037-4343-859d-e59bca5f1e43 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79e6dc26-a38b-4642-a216-1fa1213b919a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71296464-0c09-4ff2-beb3-377af77dc4cf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef472176-7f98-4f88-be5e-a101fecb46fd (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbd47222-14f1-4588-a009-9b81b55ca60d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6af40b06-0a92-454c-9277-80e89de27231 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8e954d4-54e3-491c-867c-b3b656b70f23 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5926c3ff-c995-4789-941c-d38aa7db94dc (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41e32cd5-1393-4ef1-81cb-8e3795e30682 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:19064624-81d1-4ce3-bfe4-955bad6af6a2 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dc9e4871-fb3d-4c59-81e5-2ab6e8be9b7c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:589ae3a6-8b2e-d931-d36b-1937287ab5c0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9cfdcb58-d6d7-43bb-b6e1-17172b143296 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15f8a5be-e269-2e07-60d9-1dd7bf5f5281 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb39a94e-93e6-4afe-a300-f80e8f1e0fa6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304a23-4a5f-47bc-9687-4044b43f7a20 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab8616a5-ea72-4df7-b095-54ea19ef6fba (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b95494e2-ee7a-7415-e053-2995a90ae852 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7e96b724-5f5f-43cb-8d8b-adff3e1fc779 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:352b4c3c-e419-4827-9e00-febb0164e0f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3df910c5-b6f0-4a65-9640-b702ecea49f9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e4a815eb-ea20-482a-bb67-06ab34264515 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:388fd4bc-f12f-4e55-a1e7-72aa585519fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63d61062-2700-47f4-8ab4-3bd641b81fe1 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8f72850-92d5-4f64-b9f1-657f72bfa15a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0fb57229-08ef-44d6-b40a-92b2f96ff795 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca6bbec6-5631-4436-957e-fb8707e1683d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15ffe3d8-d483-4c45-adc4-1cc8a5b68d19 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cd6fe37a-d26d-4ae8-a894-b44878e6bf8e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d67af03a-5261-4358-8787-2e729267ff7e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eee54a6-5b4c-330d-e063-6394a90a9f18 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f936b9d0-a58f-4fa5-8db9-752dabb837a6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1107f190-bef1-41cb-9393-8479b0a56040 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbd1d178-77a3-46ff-985d-307dffaed1ad (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed710c62-8ba6-4f19-b240-3ee73cd03d67 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:533245ba-7088-c929-e063-6294a90abe1d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f911748c-fb3a-fe1a-ab2a-4b40455e05ef (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35a91dd3-19d0-09cb-e063-6394a90af01b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35a95333-9fc1-7a9f-e063-6294a90a9f30 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbe7d9b9-70e4-4531-a24f-5918966d94f5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ef6c5fd-42b2-4419-9b5a-e6d63571e3a0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:283af6d2-8ea2-4225-b2e7-a2057dbdb793 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed24bb3a-bba1-4b27-8733-96619793fc15 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce12c7b1-caa9-4224-bb5f-3e20e0281d66 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m2 and 11 L/1.73 m2, respectively.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0bef10ed-e4b5-95ae-e063-6294a90a86eb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64b509bc-f398-48ad-bdcb-9904e61d9225 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79132bea-04d8-4dd9-bd31-07f0ba805c21 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fea19b14-d8ed-4954-bc54-b9240f78b3c3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73m 2 and 11 L/1.73m 2 , respectively.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ead614c-a68d-4a2f-94d0-e6404a8f8760 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aab6b411-11e9-4a16-afb6-d471ba4756e9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55f1614b-aadc-34ca-e063-6394a90ae2a7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa386ae3-ceac-4e3b-8fb1-ced3107a4c54 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a76f9909-28c9-4eb7-8ffd-ff6222fea079 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abac11e6-7ce1-491c-9ac3-61f3df54c4a4 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38f4f2fd-400b-ccc4-e063-6294a90a5f41 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0669ac77-10df-48af-bc42-55e768b69e4f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b12b76a0-4b6e-4cd4-9508-10a2c84d8beb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4619aff4-0f80-444f-858d-42e4137aa809 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cf15569c-5010-4e9b-aef0-7df4de5ed04e (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e86a610-45ef-4be7-a3ab-f656f5b32706 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a67855ff-a879-43f0-bca3-94c304348bf5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:90225548-85a8-4ea7-95d3-e8231c36fe5a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:392df14f-4d65-4be9-973b-1f0ce1013d8f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fa823ee0-0c69-6b85-da1e-9bb2e2150ea5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d524db34-99c4-4837-a532-a619f82c21ba (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b41cd15-9981-4d44-9c4b-e84168d86453 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea5c5e3c-c23f-4ec0-b1ab-6b317f3d2f91 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e5fcf5b1-263e-43e0-9424-e613d5cca3fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d48af379-bd5d-48e1-ad2d-86c493d9cbea (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6240cee7-6aa8-425c-ba46-f889a640f0fa (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ecfe765-d743-4308-9cd9-4a7b1a229ea9 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c3af30e3-27ff-4285-8e4a-81856f266b32 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ad5e8bd8-c923-40f0-a106-55620c4247d7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48a6e47a-3697-492d-9086-56e4ca0151e5 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e4778d8-8798-4da1-bb33-1aa1414b5809 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57b71a0b-c2bf-4326-9c26-0f2fe56bf5bc (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a8ba3986-1ded-44a8-8d10-d0f252a07794 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4834732f-6044-946c-e063-6394a90a5da3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08a65cf4-7749-4ceb-6895-8f4805e2b01f (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dc024ce-efc8-4690-7cb5-639c728fccac (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00332c65-edad-a153-9c78-628931daa732 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3352ee-a240-43ff-a243-29ad2bc989c7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:547d8305-bfc5-f4da-e063-6294a90a6106 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e35f833-1cf7-12eb-9567-7a191e32e138 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:66b0a3e0-70df-469e-845f-17769482304b (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a999f402-be1d-4153-b743-cfdb95ed1562 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab6fa448-7485-6644-e053-2a95a90aa181 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:93d6ddb5-7143-4917-baf7-31cbf8a90e8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bf34dd25-abe3-4587-b481-df052f085429 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74adc5e-e92d-46a7-afdc-a6464a440bde (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8cc336b-5191-7f8b-e053-2a95a90a6acb (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1d4d790-73d5-4a3b-a786-99f2c9812546 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:319bbead-bec8-4bb7-9ecb-b2e161c44b8d (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0816a066-9ee3-4c23-944d-3539fc2c12bf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5e59609f-d79d-414b-a6fc-7efb1ba5b200 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:94eac383-a89f-4128-b81c-076640b8edcf (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c971b50d-0f78-422f-abee-1c5b4e1d20e7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f5bb45e-836b-48ce-9764-2d50edcb202c (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0822300b-68c0-4e70-b1ba-8eb42cf373f7 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47412563-ec3e-44fd-9f3f-c00b9b09033a (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b367d81d-4eca-4e28-b490-34be4c003561 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c8f84c2e-5621-4435-8023-b4e090f7af02 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aec1944-86a1-490c-a734-d9dd3b52c9d6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2388bfd-7455-48ae-b396-463df0c278f0 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:beba3da1-e80d-45b4-9bd6-3ed85c9482f3 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a0fa934-ec8c-460e-86eb-11281728fe85 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74a9f020-f7a1-44e2-a452-f0e37bd3e077 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4fc50afb-67f3-4bf3-9ec3-cc12734f47fd (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33f07aac-4dc5-4f97-976a-a84f93497bc6 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0339e27d-3dbf-4c37-a14e-f53557c08e19 (opens source in a new tab)

        Divalproex label

        Version not recorded · Effective date not recorded

        Elimination Mean plasma clearance and volume of distribution for total valproate are 0.56 L/hr/1.73 m 2 and 11 L/1.73 m 2 , respectively.

  7. Projected row 457

    Medicine slug
    docetaxel
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    32
    Source count
    27
    Agreement rate
    1
    Recorded readings

    1. 116 hours

      Numeric value
      116
      Unit
      hours
      Source records
      27

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 27 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb017fd-e55e-43ef-9024-07f2d412b37b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f59f7811-70b7-4c44-99f7-4f4fdce3ed22 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/ m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00c61d11-d6b7-4618-b6f6-2592dbcc8af7 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:654319ae-e5f9-4a6a-b566-201923153b6e (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6417655-9448-4886-ba03-f57f36bcbd14 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/ m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a49c281-8cfd-4698-a9df-90ba800058ef (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e0f06bd-d190-45da-be8b-062e8de01970 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30077f79-341f-4618-9ec5-23b17b212fae (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e488100d-6728-4f44-9282-f63a805b8e13 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c806400-5fdc-4398-8475-37f700b3191f (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b9999bb-869e-4d25-838c-23c3ab280044 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2992d633-08fa-44f3-b14d-41700f24686b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3538b979-8cac-49ed-b8dc-50f73ce38c72 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14cbd8f6-e11b-4d64-aa4c-e70a2ecbf975 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fb533da-a7ba-4c2b-8e4f-8e336ba55d12 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67508df6-b96f-46fa-a792-0afcdfa9810e (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1263799c-13dc-488b-b158-b834736a4e66 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b227144-c844-4549-960c-cc3ac5c13b2b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e03d1378-6889-43d5-a34c-f96132cffa88 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0ca36d-1f54-4568-8d19-a7152addcd52 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4763744e-360e-4d37-be05-cce4114548cd (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81686d37-a13f-46e2-b439-a84eb1433634 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        E limination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f970e352-3d43-4cc4-a859-503ec37b6e22 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8fb7d980-d6c7-468b-a9f0-adff16101a4b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0ec4bcc-93ea-4c41-a4b6-95ec19491807 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:644c5035-20d2-4686-beaa-bef08e99051c (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Elimination With extended plasma sampling up to 8 to 22 days post infusion, the estimated mean total body clearance was 18 L/h/m 2 (range of means: 14 to 23) and mean terminal elimination half-life was 116 hours (range of means: 92 to 135).

  8. Projected row 458

    Medicine slug
    docetaxel
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    32
    Source count
    32
    Agreement rate
    1
    Recorded readings

    1. 113 L

      Numeric value
      113
      Unit
      L
      Source records
      32

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 32 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb017fd-e55e-43ef-9024-07f2d412b37b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f59f7811-70b7-4c44-99f7-4f4fdce3ed22 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:00c61d11-d6b7-4618-b6f6-2592dbcc8af7 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:654319ae-e5f9-4a6a-b566-201923153b6e (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6417655-9448-4886-ba03-f57f36bcbd14 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3a49c281-8cfd-4698-a9df-90ba800058ef (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a630937b-8369-74ad-b68a-f940eb16ff0f (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Mean steady state volume of distribution was 113 L.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e0f06bd-d190-45da-be8b-062e8de01970 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30077f79-341f-4618-9ec5-23b17b212fae (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e488100d-6728-4f44-9282-f63a805b8e13 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c806400-5fdc-4398-8475-37f700b3191f (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff7fb2c2-97a7-4716-a269-925ca30cf0f1 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Mean steady state volume of distribution was 113 L.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b9999bb-869e-4d25-838c-23c3ab280044 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2992d633-08fa-44f3-b14d-41700f24686b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3538b979-8cac-49ed-b8dc-50f73ce38c72 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:682a0b1a-3277-4718-a94e-9645633062bf (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Mean steady state volume of distribution was 113 L.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c85b2c62-3c33-4cbc-8b79-d5e17851a1b4 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Mean steady state volume of distribution was 113 L.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14cbd8f6-e11b-4d64-aa4c-e70a2ecbf975 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9fb533da-a7ba-4c2b-8e4f-8e336ba55d12 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67508df6-b96f-46fa-a792-0afcdfa9810e (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady-state volume of distribution was 113 L.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be3df07d-ea56-453a-25ad-c3cedc22712a (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Mean steady state volume of distribution was 113 L.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1263799c-13dc-488b-b158-b834736a4e66 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b227144-c844-4549-960c-cc3ac5c13b2b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e03d1378-6889-43d5-a34c-f96132cffa88 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3104aab1-cd6e-4ad2-8e0a-286a0c5d1940 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0ca36d-1f54-4568-8d19-a7152addcd52 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4763744e-360e-4d37-be05-cce4114548cd (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81686d37-a13f-46e2-b439-a84eb1433634 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f970e352-3d43-4cc4-a859-503ec37b6e22 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8fb7d980-d6c7-468b-a9f0-adff16101a4b (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a0ec4bcc-93ea-4c41-a4b6-95ec19491807 (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:644c5035-20d2-4686-beaa-bef08e99051c (opens source in a new tab)

        Docetaxel label

        Version not recorded · Effective date not recorded

        Distribution Mean steady state volume of distribution was 113 L.

  9. Projected row 459

    Medicine slug
    dofetilide
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    13
    Source count
    13
    Agreement rate
    1
    Recorded readings

    1. 90%

      Numeric value
      90
      Unit
      %
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c1a5a6d-bd69-473c-8caa-d0d242b7708d (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2 to 3 hours in the fasted state.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4552d82a-dd28-410c-9642-1af060832b47 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2 to 3 hours in the fasted state.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e60aa4b-72c2-4ef4-ab01-c9cf94240ff1 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is > 90%, with maximal plasma concentrations occurring at about 2 hours to 3 hours in the fasted state.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ccbb23-ae03-44bd-b438-0b0a8388d56b (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2 to 3 hours in the fasted state.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d943c6-1960-4318-9e6f-6bf69ac49953 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26de5f8c-8cec-46f6-a468-69451758a278 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8323987-90fe-4e6c-a71c-76e3c501713c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85f2b35c-31d5-4161-b342-c781d23945a5 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2 to 3 hours in the fasted state.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02438044-d6a3-49e9-a1ac-3aad21ef2c8c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2–3 hours in the fasted state.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff8d66a-ed43-46dd-97de-3dd21a7f2572 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28fe0cac-62fd-997d-8065-561aaf1541c4 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2-3 hours in the fasted state.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cb2ef7d-e35b-483b-9985-cfef99d7b96f (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2–3 hours in the fasted state.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6caaf44-4a3e-46ef-85fa-f97f682fbdd6 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        Pharmacokinetics, General Absorption and Distribution: The oral bioavailability of dofetilide is >90%, with maximal plasma concentrations occurring at about 2 to 3 hours in the fasted state.

  10. Projected row 460

    Medicine slug
    dofetilide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    13
    Source count
    13
    Agreement rate
    1
    Recorded readings

    1. 10 hours

      Numeric value
      10
      Unit
      hours
      Source records
      13

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 13 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c1a5a6d-bd69-473c-8caa-d0d242b7708d (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 to 3 days, with an accumulation index of 1.5 to 2.0.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4552d82a-dd28-410c-9642-1af060832b47 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 to 3 days, with an accumulation index of 1.5 to 2.0.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e60aa4b-72c2-4ef4-ab01-c9cf94240ff1 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 days to 3 days, with an accumulation index of 1.5 to 2.0.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ccbb23-ae03-44bd-b438-0b0a8388d56b (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 to 3 days, with an accumulation index of 1.5 to 2.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d943c6-1960-4318-9e6f-6bf69ac49953 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26de5f8c-8cec-46f6-a468-69451758a278 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2-3 days, with an accumulation index of 1.5 to 2.0.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8323987-90fe-4e6c-a71c-76e3c501713c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85f2b35c-31d5-4161-b342-c781d23945a5 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 to 3 days, with an accumulation index of 1.5 to 2.0.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02438044-d6a3-49e9-a1ac-3aad21ef2c8c (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff8d66a-ed43-46dd-97de-3dd21a7f2572 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:28fe0cac-62fd-997d-8065-561aaf1541c4 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2-3 days, with an accumulation index of 1.5 to 2.0.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cb2ef7d-e35b-483b-9985-cfef99d7b96f (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2–3 days, with an accumulation index of 1.5 to 2.0.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e6caaf44-4a3e-46ef-85fa-f97f682fbdd6 (opens source in a new tab)

        Dofetilide label

        Version not recorded · Effective date not recorded

        The terminal half-life of dofetilide is approximately 10 hours; steady state plasma concentrations are attained within 2 to 3 days, with an accumulation index of 1.5 to 2.0.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=450

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy